

**AMENDMENTS TO THE CLAIMS**

**This listing of claims will replace all prior versions and listings of claims in the application:**

**LISTING OF CLAIMS:**

**1. (currently amended):** A method ~~for~~ of treating cerebral infarction, comprising parenterally administering to a human between about 100 mg to about 2,000 mg of (2R)-2-propyloctanoic acid or a salt thereof for about 0.5 to about 3 hours once a day to a mammal for a period of treatment lasting from 1 to 100 days.

**2-5. (canceled).**

**6. (original):** The method according to claim 1, wherein the parenteral administration is intravenous administration.

**7. (original):** The method according to claim 6, wherein the intravenous administration is continuous administration.

**8. (original):** The method according to claim 7, wherein the continuous administration is infusion bag administration.

**9. (canceled).**

**10. (currently amended):** The method according to claim [[9]] 1, wherein the administration period is from 1 day to 10 days.

**11. (original):** The method according to claim 10, wherein the administration period is 3 days, 4 days, 5 days, 6 days or 7 days.

**12. (original):** The method according to claim 11, wherein the administration period is 7 days.

**13. (original):** The method according to claim 1, wherein the dose per 1 kg of body weight of a patient is within a range of about 2 mg to about 12 mg.

**14. (original):** The method according to claim 13, wherein the dose per 1 kg of body weight of a patient is about 2 mg, about 4 mg, about 6 mg, about 8 mg, about 10 mg or about 12 mg.

**15. (original):** The method according to claim 14, wherein the dose per 1 kg of body weight of a patient is about 4 mg or about 8 mg.

**16. (original):** The method according to claim 1, which is a method for inhibition of S-100 $\beta$  increase.

**17. (withdrawn):** A method for inhibition of S-100 $\beta$  increase, which comprises parenterally administering to a mammal an effective amount of (2R)-2-propyloctanoic acid or a salt thereof.

**18. (withdrawn):** The method according to claim 17, wherein the amount per dose in the parenteral administration is within a range of about 100 mg to about 2,000 mg.

**19. (withdrawn):** The method according to claim 17, wherein the parenteral administration is intravenous administration.

**20. (withdrawn):** The method according to claim 17, wherein the dose of parenteral administration per once a day during an administration period of 1 day to 100 days is within a range of about 100 mg to about 2,000 mg.

**21. (withdrawn):** The method according to claim 17, wherein the dose per 1 kg of body weight of a patient is within a range of about 2 mg to about 12 mg.

**22-23. (canceled).**

**24. (withdrawn):** A method for preventing and/or treating cerebral infarction which comprises parenterally administering to a mammal an effective amount of (2R)-2-propyloctanoic acid or a salt thereof in combination with an effective amount of a tissue plasminogen activator.

**25. (withdrawn):** The method according to claim 24, wherein the dose of (2R)-2-propyloctanoic acid or a salt thereof per 1 kg of body weight of a patient is about 4 mg or about 8 mg, and the dose of the tissue plasminogen activator per 1 kg of body weight of a patient is about 0.6 mg or about 0.9 mg.

**26. (withdrawn):** The method according to claim 25, wherein the administration is started within 3 hours after onset of the cerebral infarction.

**27. (withdrawn):** A parenterally administered composition for preventing and/or treating cerebral infarction which comprises (2R)-2-propyloctanoic acid or a salt thereof in combination with a tissue plasminogen activator.

**28. (canceled).**

**29. (original):** The method according to claim 1, wherein (2R)-2-propyloctanoic acid is used.

**30. (withdrawn):** The composition according to claim 27, wherein (2R)-2-propyloctanoic acid is comprised.

**31. (canceled).**

**32. (withdrawn):** A method for treating cerebral infarction, which comprises continuously administering to a mammal intravenously (2R)-2-propyloctanoic acid using an infusion bag at a dose of about 4 mg or about 8 mg per 1 kg of body weight during administration period for 7 days.

**33. (withdrawn):** The method according to claim 17, wherein (2R)-2-propyloctanoic acid is used.

**34. (withdrawn):** The method according to claim 24, wherein (2R)-2-propyloctanoic acid is used.

**35. (currently amended):** A method for treating cerebral infarction, comprising continuously administering (2R)-2-propyloctanoic acid intravenously to a ~~mammal~~ human using an infusion bag at a dose of about 4 mg or about 8 mg per 1 kg of body weight for about 1 hour once a day during an administration period of 7 days.

**36. (new):** The method according to claim 1, wherein the period of time is 1 hour.